Can aspirin induce a cough?

Can Aspirin Cause Cough?

Yes, aspirin can definitively cause cough, primarily through two distinct mechanisms: as part of Aspirin-Exacerbated Respiratory Disease (AERD) with associated bronchospasm and rhinitis, or rarely as isolated cough without bronchoconstriction.

Primary Mechanism: AERD (Aspirin-Exacerbated Respiratory Disease)

The most clinically significant way aspirin causes cough is through AERD, a well-characterized syndrome affecting approximately 7% of adults with asthma 1. In AERD, aspirin and other COX-1 inhibiting NSAIDs trigger sudden and often severe upper and lower respiratory tract symptoms, including cough, within 3 hours of ingestion 1, 2.

Key Clinical Features of AERD:

• Classic triad: Chronic rhinosinusitis with nasal polyps, asthma, and respiratory reactions to aspirin/NSAIDs 1
• Timing: Symptoms develop within 20 minutes to 3 hours after aspirin ingestion 3
• Associated symptoms: Cough accompanied by bronchospasm, rhinorrhea, nasal congestion, dyspnea, and sometimes flushing 1, 2
• Severity: Can range from mild cough to violent bronchospasm and respiratory arrest 2

Who Is at Risk:

• Adults with asthma (especially those with nasal polyps—one-third have AERD) 1
• Patients with chronic rhinosinusitis
• Rare in children 1, 3
• The FDA label explicitly warns that aspirin may cause asthma (wheezing) as part of severe allergic reactions 4

Rare Presentation: Isolated Cough Without Bronchospasm

A distinct and uncommon presentation exists where aspirin causes isolated cough without any bronchoconstriction or wheezing 5. This represents a novel type of aspirin hypersensitivity where:

• Cough occurs within 15 minutes of aspirin exposure
• No change in FEV1 or audible wheezing
• May be accompanied by perspiration and flushing
• Other COX inhibitors trigger the same response 5

Mechanism of Aspirin-Induced Cough

The pathophysiology involves COX-1 inhibition leading to:

• Shunting of arachidonic acid metabolism toward cysteinyl leukotriene overproduction 2, 6
• Removal of protective prostaglandin E2's bronchodilator effect 2
• Chronic overproduction of leukotrienes even at baseline in AERD patients 7, 6

Clinical Management Algorithm

If Aspirin-Induced Cough Is Suspected:

1. Establish the diagnosis:

   • History of cough/respiratory symptoms within 3 hours of aspirin/NSAID use
   • Presence of asthma, chronic rhinosinusitis, or nasal polyps strongly suggests AERD 1
   • If history is typical (≥2 respiratory reactions to different NSAIDs or severe reaction requiring hospitalization), formal aspirin challenge is NOT needed 1
   • If history is unclear, perform controlled oral aspirin challenge in supervised setting 1

2. Immediate action:

   • Discontinue aspirin and all COX-1 inhibiting NSAIDs 8
   • Observe if cough resolves after drug withdrawal 8

3. Alternative analgesics:

   • Selective COX-2 inhibitors are safe and recommended for patients with any NSAID hypersensitivity phenotype, including AERD 1
   • Reactions to COX-2 inhibitors are extremely rare in AERD patients 1

4. If aspirin is medically necessary (e.g., cardiovascular indications):

   • Consider aspirin desensitization protocol in specialized setting 1
   • Pretreat with leukotriene modifiers and inhaled corticosteroid/long-acting beta-agonist 1

Critical Pitfalls to Avoid

• Do not assume all cough with aspirin is benign: In patients with underlying asthma, this can progress to life-threatening bronchospasm 2, 3
• Do not overlook drug-induced cough in the differential: Many cases are misdiagnosed when chest imaging is normal 8
• Do not perform aspirin challenges outside supervised settings: Emergency treatment must be immediately available 2, 3
• Recognize that aspirin avoidance alone does not control AERD: These patients typically have refractory rhinosinusitis and asthma requiring aggressive medical/surgical management 1

Bottom Line

Aspirin-induced cough is a real and potentially serious adverse effect, primarily occurring as part of AERD in adults with asthma and nasal polyps 1. The 2022 Drug Allergy Practice Parameter provides clear guidance: use selective COX-2 inhibitors as safe alternatives when NSAIDs are needed in these patients 1. The diagnosis is typically clinical, and formal challenge testing should be reserved for uncertain cases 1.